Residual and Recurrent Gastrointestinal Stromal Tumors With KIT Mutations: Findings at First Follow-Up CT After Imatinib Treatment
July 23rd, 2009 Posted by: admin
OBJECTIVE. The purpose of this study was to correlate findings on
the first follow-up CT after treatment with imatinib in patients with residual
or recurrent gastrointestinal stromal tumors (GISTs) with the different types
of KIT mutation present at initial resection.
CONCLUSION. Residual and recurrent GISTs with KIT mutation
of exon 11 deletion more frequently showed both tumor shrinkage and cystic
change on 2-month follow-up CT images after the start of imatinib treatment
than did other mutation types.
Similar Posts:
- Valproic acid and phenobarbital blood levels during the first month of treatment with the ketogenic diet
- Serial Follow-Up MRI of Indeterminate Cystic Lesions of the Pineal Region: Experience at a Rural Tertiary Care Referral Center
- Clinical phenotype of posterior polymorphous corneal dystrophy in a family with a novel ZEB1 mutation
- Recurrent wheezing after respiratory syncytial virus or non-respiratory syncytial virus bronchiolitis in infancy: a 3-year follow-up
- Incidence of redetachment 6 months after scleral buckling surgery
- Diffusion-Weighted MRI of Peritoneal Tumors: Comparison With Conventional MRI and Surgical and Histopathologic Findings–A Feasibility Study
- Follow-up of residual shunt after patent foramen ovale closure
- Retroperitoneal Extragonadal Nonseminomatous Germ Cell Tumor with Synchronous Orbital Metastasis
- CTLA4 exon 1 and promoter polymorphisms in patients with multiple sclerosis
- CT and PET/CT Findings of T-Cell Lymphoma